Compositions and methods for stabilizing biomolecules

Thermostable solid-state lipid nanoparticles, optimized using AI-guided screening, address the instability of LNPs by maintaining bioactivity and facilitating cold-chain-free storage and microneedle patch delivery for RNA vaccines.

WO2026128816A1 Publication Date: 2026-06-18MASSACHUSETTS INST OF TECH
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
MASSACHUSETTS INST OF TECH
Filing Date
2025-12-12
Publication Date
2026-06-18

AI Technical Summary

⚠Technical Problem

Lipid nanoparticles (LNPs) used in RNA vaccines are inherently unstable, requiring stringent storage conditions and limiting their global distribution, especially in resource-limited settings, and current excipient-based stabilization methods are inefficient and confined to a limited design space.

⚗Method used

Development of thermostable, solid-state lipid nanoparticles stabilized by a combination of polymers, lipids, and amino acids, optimized using an AI-guided high-throughput screening framework (AGENT) to enhance stability and adaptability for microneedle patch delivery.

🎯Benefits of technology

The optimized solid-state LNPs maintain bioactivity at 37°C for at least one month, enabling cold-chain-free storage and effective delivery via microneedle patches, with antibody responses comparable to freshly prepared vaccines.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

Disclosed are lipid nanoparticles and methods of use thereof. Also disclosed herein are methods of identifying excipients, adjuvants, and additives to improve the stability of lipid nanoparticle compositions.
Need to check novelty before this filing date? Find Prior Art